GRP78 confers breast cancer cells with resistance to radiation, anti-hormonal therapy, combretastatin A4P (anti-vascular agent) contortrostatin (anti-angiogenic agent) [76], microtubule-interfering agents [70], HDAC inhibitors, vinca alkaloids [70], and gemcitabine [77]. The gene discussed is HSPA5; the disease is breast cancer.